Success Metrics

Clinical Success Rate
100.0%

Based on 5 completed trials

Completion Rate
100%(5/5)
Active Trials
1(10%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_1
4
40%
Ph phase_2
5
50%
Ph phase_3
1
10%

Phase Distribution

4

Early Stage

5

Mid Stage

1

Late Stage

Phase Distribution10 total trials
Phase 1Safety & dosage
4(40.0%)
Phase 2Efficacy & side effects
5(50.0%)
Phase 3Large-scale testing
1(10.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

5 of 5 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

10

all time

Status Distribution
Active(1)
Completed(5)
Other(4)

Detailed Status

Completed5
unknown4
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
10
Active
1
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 14 (40.0%)
Phase 25 (50.0%)
Phase 31 (10.0%)

Trials by Status

unknown440%
completed550%
recruiting110%

Recent Activity

1 active trials
Showing 5 of 10
recruitingphase_2

Orelabrutinib Combined With Pemetrexed For Relapsed/Refractory Central Nervous System Lymphoma

NCT05209620
completedphase_2

A Study of ICP-022 in Patients With R/R DLBCL

NCT04438005
completedphase_2

A Study of ICP-022 in the Treatment of Recurrent or Refractory Waldenstrom Macroglobulinemia

NCT04440059
completedphase_2

A Study to Evaluate ICP-022 in Patients With R/R Marginal Zone Lymphoma (MZL)

NCT03797456
unknownphase_1

A Study to Evaluate ICP-022 in Patients With R/R Mantle Cell Lymphoma (MCL)

NCT03494179
View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials
NCT05209620Phase 2

Orelabrutinib Combined With Pemetrexed For Relapsed/Refractory Central Nervous System Lymphoma

Recruiting
NCT04438005Phase 2

A Study of ICP-022 in Patients With R/R DLBCL

Completed
NCT04440059Phase 2

A Study of ICP-022 in the Treatment of Recurrent or Refractory Waldenstrom Macroglobulinemia

Completed
NCT03797456Phase 2

A Study to Evaluate ICP-022 in Patients With R/R Marginal Zone Lymphoma (MZL)

Completed
NCT03494179Phase 1

A Study to Evaluate ICP-022 in Patients With R/R Mantle Cell Lymphoma (MCL)

Unknown
NCT04578613Phase 3

ICP-022 Versus Chlorambucil Combined With Rituximab in the Treatment of Untreated CLL/SLL

Unknown
NCT04305197Phase 1

A Study of ICP-022 in Patients With Systemic Lupus Erythematosus (SLE)

Completed
NCT04438044Phase 2

A Study to Evaluate ICP-022 in Patients With R/R PCNSL and SCNSL

Unknown
NCT03493217Phase 1

A Study to Evaluate ICP-022 in Patients With CLL/ SLL

Unknown
NCT03189017Phase 1

A Phase I Study of ICP-022 in Healthy Subjects

Completed

All 10 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
10